sbynews

DelMarVa’s Premier Source for Conservative News, Opinion, Analysis, and Human Interest

Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349

The opinions expressed by columnists are their own and do not represent our advertisers

Covid shot maker Moderna hails ‘new paradigm’ as its cancer mRNA vaccine slashes risk of relapse or death in melanoma patients by 44%

A cancer vaccine that uses the same technology as Covid shots has been shown to slash the risk of tumors returning in advanced melanoma patients.

The shot, combined with an immunotherapy drug, reduced the chance of relapse or death in sufferers after surgery by 44 percent, compared to the drug on its own.

Using pieces of genetic code from patients’ tumors, the vaccine effectively ‘teaches’  the body to fight off cancer. Every shot is tailored to a specific patient, meaning no two will be the same.

Pharma giants Merck and Moderna – who are co-developing the technological advance – heralded the results as a ‘tremendous step forward’ and a ‘new paradigm’ moment.

They will now ‘rapidly’ seek approval for a final stage clinical trial that will confirm the vaccine’s efficacy on a much larger group of patients. If successful, it could be approved within six months of the study’s end.

More

5 thoughts on “Covid shot maker Moderna hails ‘new paradigm’ as its cancer mRNA vaccine slashes risk of relapse or death in melanoma patients by 44%”

Leave a Comment

Your email address will not be published. Required fields are marked *